EMA Authorised: Spexotras (trametinib dimethyl sulfoxide) — Novartis Europharm Limited

View source ↗

Summary

The European Medicines Agency authorised Spexotras (trametinib dimethyl sulfoxide) for glioma. The product carries orphan medicine designation and is marketed b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• Spexotras (trametinib dimethyl sulfoxide)

Snippet

Status: Authorised. Therapeutic area: Glioma. MAH: Novartis Europharm Limited. Decision date: 03/11/2025. Orphan medicine